Abstract
Acute promyelocytic leukemia (APL) treatment often relies on arsenic trioxide (As₂O₃), which induces apoptosis via endoplasmic reticulum (ER) stress. This study investigates the role of SUMO-specific protease 1 (SENP1) in this process. Using NB4 cells, researchers demonstrated that while SENP1 deficiency does not affect spontaneous apoptosis or differentiation, it significantly sensitizes cells to As₂O₃-induced death. Mechanistically, SENP1 knockdown leads to the accumulation of SUMOylated XBP1, suppressing the expression of survival-related target genes like Erdj4 and Sec61a. These findings highlight SENP1 as a potential therapeutic target to enhance the efficacy of APL treatments.
Introduction
Acute Promyelocytic Leukemia (APL) is a subtype of leukemia characterized by the fusion protein PML-RARα. While the combination of All-Trans Retinoic Acid (ATRA) and arsenic trioxide (As₂O₃) has revolutionized APL therapy, resistance remains a clinical challenge. Arsenic trioxide works by triggering the Unfolded Protein Response (UPR) due to ER stress. Central to this response is XBP1, a transcription factor whose activity is regulated by SUMOylation. This study explores how SENP1, a de-SUMOylating enzyme, modulates XBP1 activity and influences the apoptotic response to arsenic.
Methodology
The study employed the human APL cell line NB4. SENP1 expression was silenced using retroviral-delivered siRNA. The efficiency of this knockdown was verified via RT-qPCR. Apoptosis was quantified using Annexin V/PI staining followed by flow cytometry. Cell differentiation was assessed by measuring the expression of the surface marker CD11b. To investigate the molecular mechanism, the researchers used immunoprecipitation to detect SUMOylated XBP1 and RT-qPCR to measure the mRNA levels of XBP1 target genes (Erdj4, Sec61a) and ER stress markers (GRP78, GADD153).
Results
SENP1 Knockdown and Baseline Cellular Effects
Initial experiments confirmed that SENP1 mRNA levels were significantly reduced following siRNA transfection. Crucially, the deficiency of SENP1 alone did not trigger spontaneous apoptosis or induce cell differentiation in the absence of other stimuli. As shown in the flow cytometry data, the baseline apoptosis rates and ATRA-induced CD11b expression remained largely unchanged between control and SENP1-knockdown groups.
Sensitization to Arsenic Trioxide
The role of SENP1 became evident upon treatment with As₂O₃. In control cells, arsenic treatment resulted in an apoptosis rate of approximately 37%. However, in SENP1-deficient cells, this rate increased dramatically to 66%. This indicates that SENP1 acts as a survival factor specifically during periods of drug-induced stress.
The Molecular Mechanism: XBP1 and ER Stress
The researchers found that SENP1 deficiency leads to an accumulation of SUMOylated (inactive) XBP1. Under normal conditions, SENP1 de-SUMOylates XBP1, allowing it to activate target genes like Erdj4 and Sec61a which help the cell manage ER stress. Without SENP1, these protective genes are downregulated, and the ER stress induced by arsenic becomes overwhelming, leading to the upregulation of pro-apoptotic markers like GADD153 and subsequent cell death.
Discussion and Conclusion
This study identifies the SENP1/XBP1 axis as a critical regulator of the ER stress response in APL cells. By maintaining XBP1 in its active, de-SUMOylated state, SENP1 helps leukemia cells survive the proteotoxic stress caused by arsenic trioxide. Inhibiting SENP1 could therefore represent a potent strategy to sensitize APL cells to existing therapies. Future research should focus on validating these findings in in vivo models and exploring the potential of SENP1 as a clinical biomarker for treatment response.
Summary updated